Global Hyperphosphatemia Drug Market Forecast 2019-2027

Wednesday, November 28, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 27, 2018 /PRNewswire/ -- KEY FINDINGSThe global hyperphosphatemia drugs market is expected to grow

at a CAGR of 16.13% during the forecast period of 2019-2027. The market is expected to be worth $xx million by the year 2027. Increasing prevalence of chronic diseases, unmet medical needs, a high proportion of the elderly population and the rise in
public awareness are the major drivers for the hyperphosphatemia drugs market.Read the full report: MARKET INSIGHTSThe market segmentation is done on the basis of the formulation.The various types of phosphate binders include calcium-based phosphate binders, aluminium-based phosphate binders, magnesium-based phosphate binders, iron-based phosphate binders and other phosphate binders.Of these, the Calcium-based phosphate binder's held the largest market share of xx% in 2018 and is expected to continue its dominance during the forecast period.The global hyperphosphatemia market is facing many restraints due to various limitations levied by the Food and Drug Administration (FDA) and the growing side effects of the hyperphosphatemia drugs observed in some patients.In spite of this, the Asia-Pacific hyperphosphatemia drug market is showing much promise in terms of making various opportunities available for the market to grow and expand.REGIONAL INSIGHTSThe hyperphosphatemia drugs market in North America is expected to hold the largest share by the end of the forecast period due to changing dietary habits, increasing osteoporosis cases and a rising ageing population in this region.The Europe hyperphosphatemia drugs market is also fast growing at a CAGR of xx%.However, it is the Asia-Pacific market which is expected to propel the market growth, with the Indian hyperphosphatemia drugs market exhibiting the highest growth at a CAGR of xx% during the forecast period.COMPETITIVE INSIGHTSThe major companies in the hyperphosphatemia drugs market include, Johnson And Johnson, Amag Pharmaceuticals, Cipla, Keryx Biopharmaceuticals, Sun Pharm Inc., Zeria Pharmaceutical, DSM Biotech Pharmacal , Ultragenyx, Fermenta Biotech Ltd, Pfizer Inc., Bruno Pharmaceutical Spa, Roche Diagnostics Corporation, Vifor Pharma, Sanofi R.H. Moore Drug Co., Shire, and Fresenius Medical Care.Companies mentioned1. AMAG PHARMACEUTICALS2. BIOTECH PHARMACAL3. BRUNO FARMACEUTICI SPA4. CIPLA5. FERMENTA BIOTECH LTD.6. FRESENIUS MEDICAL CARE7. JOHNSON AND JOHNSON8. KERYX BIOPHARMACEUTICALS INC.9. PFIZER INC.10. ROCHE DIAGNOSTICS CORPORATION11. ROYAL DSM N.V.12. SANOFI13. SHIRE14. SUN PHARMACEUTICAL INDUSTRIES LTD.15. ULTRAGENYX PHARMACEUTICAL INC.16. ZERIA PHARMACEUTICALRead the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store